|
1
|
Hubbeling H, Silverman E, Tomas AA, Tringale K, Wijetunga N, Hajj C, Mailankody S, Batlevi C, Dahi P, Giralt S, Lin R, Park J, Scordo M, Sauter C, Shah G, Perales M, Palomba M, Shouval R, Yahalom J, Imber B. Radiotherapy for Relapse after Chimeric Antigen Receptor T Cell Therapy in Hematologic Malignancies. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
|
2
|
Okosun J, Bödör C, Batlevi C, Nagy N, Michot J, Schneider T, Alizadeh H, Simon Z, Vose J, Younes A, Ribrag V, Fitzgibbon J, Yang J, Agarwal S, Newberry K, Michaud N. EZH2 GAIN-OF-FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.6_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Okosun
- Hematology, Barts Cancer Institute; Queen Mary University of London; London United Kingdom
| | - C. Bödör
- Hematology; Semmelweis University; Budapest Hungary
| | - C. Batlevi
- Medical Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - N. Nagy
- Cancer Research; Semmelweis University; Budapest Hungary
| | - J. Michot
- Hematology and Innovative Drugs; Gustave Roussy; Villejuif France
| | - T. Schneider
- Medical Oncology and Hematology; National Institute of Oncology; Budapest Hungary
| | - H. Alizadeh
- Internal Medicine; University of Pecs; Pecs Hungary
| | - Z. Simon
- Biochemistry and Molecular Biology; University of Debrecen; Debrecen Hungary
| | - J. Vose
- Oncology & Hematology; University of Nebraska Medical Center; Omaha United States
| | - A. Younes
- Medical Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - V. Ribrag
- DITEP; Gustave Roussy; Villejuif France
| | - J. Fitzgibbon
- Hematology, Barts Cancer Institute; Queen Mary University of London; London United Kingdom
| | - J. Yang
- Biostatistics; Epizyme; Cambridge United States
| | - S. Agarwal
- Chief Medical Officer; Epizyme; Cambridge United States
| | | | - N.R. Michaud
- Translational Medicine; Epizyme; Cambridge United States
| |
Collapse
|
|
3
|
Imber B, Palomba M, DeSelm C, Batlevi C, Dahi P, Giralt S, Noy A, Park J, Sauter C, Scordo M, Shah G, Sadelain M, Perales M, Yahalom J. MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.68_2630] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- B.S. Imber
- Department of Radiation Oncology; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - M.L. Palomba
- Lymphoma Service & Center for Cellular Therapeutics; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - C. DeSelm
- Radiation Oncology; Washington University School of Medicine; St. Louis MO United States
| | - C. Batlevi
- Lymphoma Service & Center for Cellular Therapeutics; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - P.B. Dahi
- Adult Bone Marrow Transplant Service; Department of Medicine, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - S. Giralt
- Adult Bone Marrow Transplant Service; Department of Medicine, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A.M. Noy
- Lymphoma Service; Department of Medicine, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - J.H. Park
- Center for Cellular Therapeutics; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - C.S. Sauter
- Adult Bone Marrow Transplant Service; Department of Medicine, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - M. Scordo
- Adult Bone Marrow Transplant Service; Department of Medicine, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - G. Shah
- Adult Bone Marrow Transplant Service; Department of Medicine, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - M. Sadelain
- Center for Cell Engineering and Immunology Program; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - M. Perales
- Adult Bone Marrow Transplant Service; Department of Medicine, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - J. Yahalom
- Department of Radiation Oncology; Memorial Sloan Kettering Cancer Center; New York NY United States
| |
Collapse
|
|
4
|
Batlevi C, Palomba M, Park J, Mead E, Santomasso B, Riviere I, Wang X, Senechal B, Furman R, Yang J, Kane P, Hall M, Bernal Y, Lund N, Diamonte C, Pineda J, Halton E, Moskowitz C, Younes A, Sadelain M, Brentjens R. PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION. Hematol Oncol 2019. [DOI: 10.1002/hon.124_2629] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C.L. Batlevi
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - M.L. Palomba
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - J. Park
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - E. Mead
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - B. Santomasso
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - I. Riviere
- Michael G. Harris Cell Therapy and Cell Engineering Facility; New York NY United States
| | - X. Wang
- Michael G. Harris Cell Therapy and Cell Engineering Facility; New York NY United States
| | - B. Senechal
- Michael G. Harris Cell Therapy and Cell Engineering Facility; New York NY United States
| | - R. Furman
- Department of Medicine; Weil Cornell Medical Center; New York United States
| | - J. Yang
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - P. Kane
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - M. Hall
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - Y. Bernal
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - N. Lund
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Diamonte
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - J. Pineda
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - E. Halton
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Moskowitz
- Department of Medicine; University of Miami Sylvester Cancer Center; Miami United States
| | - A. Younes
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - M. Sadelain
- Center for Cell Engineering; New York NY United States
| | - R. Brentjens
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| |
Collapse
|
|
5
|
Batlevi C, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz C, Noy A, Palomba M, Portlock C, Straus D, Boccomini C, Tucci A, Zelenetz A, Seshan V, Luminari S, Marcheselli L, Federico M, Younes A. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.109_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C.L. Batlevi
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - F. Sha
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Alperovich
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Ni
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - K. Smith
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - Z. Ying
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - P. Hamlin
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S.M. Horwitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Kumar
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M. Matasar
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A.J. Moskowitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C.H. Moskowitz
- Department of Medicine; University of Miami, Sylvester Cancer Center; Miami United States
| | - A. Noy
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M.L. Palomba
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Portlock
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - D. Straus
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Boccomini
- ASO Città della Salute e della Scienza di Torino; Ematologia; Turin Italy
| | - A. Tucci
- Department of Hematology; Spedali Civili di Brescia; Brescia Italy
| | - A.D. Zelenetz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - V.E. Seshan
- Department of Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York United States
| | - S. Luminari
- Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine, Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine; University of Modena and Reggio Emilia; Modena Italy
| | - L. Marcheselli
- Department of Medical and Surgical Sciences, and FIL Trial Office; University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine, Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine; University of Modena and Reggio Emilia; Modena Italy
| | - A. Younes
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| |
Collapse
|
|
6
|
Bobillo S, Joffe E, Lavery J, Noy A, Palomba L, Straus D, Kumar A, Batlevi C, Horwitz S, Moskowitz A, Hamlin P, Zelenetz A, Matasar M, von Keudell G, Sermer D, Yahalom J, Dogan A, Seshan V, Younes A. CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB-ERA. Hematol Oncol 2019. [DOI: 10.1002/hon.60_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Bobillo
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - E. Joffe
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - J. Lavery
- Department of Epidemiology and Biostatistics; Memorian Sloan Kettering Cancer Center; New York NY United States
| | - A. Noy
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - L. Palomba
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - D.J. Straus
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A. Kumar
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - C. Batlevi
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - S. Horwitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A. Moskowitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - P. Hamlin
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A. Zelenetz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - M. Matasar
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - G. von Keudell
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - D. Sermer
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| | - J. Yahalom
- Radiation Oncology; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A. Dogan
- Department of Pathology; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - V. Seshan
- Department of Epidemiology and Biostatistics; Memorian Sloan Kettering Cancer Center; New York NY United States
| | - A. Younes
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York NY United States
| |
Collapse
|
|
7
|
Younes A, Batlevi C, Cohen J, Kelly K, Landsburg D, Patel K, Phillips T, Smith S, Westin J, Ma A, Grayson D, Barta S. DOSE FINDING STUDY TO ASSESS SAFETY, PK AND EFFICACY OF FIMEPINOSTAT (CUDC-907) WITH VENETOCLAX OR RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.9_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Younes
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - C.L. Batlevi
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - J.B. Cohen
- Hematology & Medical Oncology; Emory University Winship Cancer Institute; Atlanta United States
| | - K. Kelly
- Department of Medicine; University of Southern California, Norris Cancer Center Hospital; Los Angeles United States
| | - D.J. Landsburg
- Department of Medicine; University of Pennsylvania, Perelman Center; Philadelphia United States
| | - K. Patel
- Oncology; Swedish Cancer Institute; Seattle United States
| | - T. Phillips
- Rogel Cancer Center; University of Michigan; Ann Arbor United States
| | - S. Smith
- Hematology/Oncology; University of Chicago; Chicago United States
| | - J. Westin
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - A.W. Ma
- Research & Development; Curis, Inc.; Lexington United States
| | - D. Grayson
- Research & Development; Curis, Inc.; Lexington United States
| | - S. Barta
- Department of Medicine; University of Pennsylvania, Perelman Center; Philadelphia United States
| |
Collapse
|
|
8
|
Rajeeve S, Bobillo S, Zelenetz A, Straus D, Palomba M, Noy A, Horwitz S, Moskowitz A, Hamlin P, Matasar M, Kumar A, Batlevi C, von Keudell G, Yahalom J, Dogan A, Drill E, Younes A, Joffe E. INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP-LIKE REGIMENS. Hematol Oncol 2019. [DOI: 10.1002/hon.74_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- S. Rajeeve
- Department of Medicine; Icahn School of Medicine at Mount Sinai; New York United States
| | - S.V. Bobillo
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - A.D. Zelenetz
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - D.J. Straus
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - M.L. Palomba
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - A. Noy
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - S.M. Horwitz
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - A.J. Moskowitz
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - P.A. Hamlin
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - M.J. Matasar
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - A. Kumar
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - C.L. Batlevi
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - G. von Keudell
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - J. Yahalom
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - A. Dogan
- Hematopathology service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - E. Drill
- Epidemiology and Biostatistics; Memorial Sloan-Kettering Cancer Center; New York United States
| | - A. Younes
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| | - E. Joffe
- Lymphoma service; Memorial Sloan-Kettering Cancer Center; New York United States
| |
Collapse
|
|
9
|
Nayak L, Iwamoto F, Ferreri A, Santoro A, Singer S, Batlevi C, Batchelor T, Rubenstein J, Johnston P, Ramchandren R, Soussain C, Drappatz J, Becker K, Witzens-Harig M, Illerhaus G, Herrera A, Masood A, Shipp M. CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- L. Nayak
- Center for Neuro-oncology; Dana-Farber Cancer Institute; Boston USA
| | - F.M. Iwamoto
- Division of Neuro-Oncology; Columbia University Medical Center; New York USA
| | - A.J. Ferreri
- Unit of Lymphoid Malignancies, Department of Onco-Hematology; IRCCS San Raffaele Scientific Institute; Milan Italy
| | - A. Santoro
- Department of Medical Oncology and Hematology, Humanitas Cancer Center; Humanitas University; Milan Italy
| | - S. Singer
- Neurological Oncology Division; Hackensack University Medical Center; Hackensack USA
| | - C. Batlevi
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - T. Batchelor
- Department of Neurology; Massachusetts General Hospital; Boston USA
| | - J. Rubenstein
- Hematology and Blood and Marrow Transplant; University of California San Francisco Medical Center; San Francisco USA
| | - P. Johnston
- Hematology and Blood and Marrow Transplant; Mayo Clinic; Rochester USA
| | - R. Ramchandren
- Department of Hematology/Oncology; Barbara Ann Karmanos Cancer Institute; Detroit USA
| | - C. Soussain
- Department of Hematology; Institut Curie, Hôpital René-Huguenin; Saint-Cloud France
| | - J. Drappatz
- Division of Hematology/Oncology, Hillman Cancer Center; University of Pittsburgh Medical Center; Pittsburgh USA
| | - K. Becker
- Cancer Immunology; Yale Cancer Center; New Haven USA
| | - M. Witzens-Harig
- Department of Internal Medicine; University Hospital Heidelberg; Heidelberg Germany
| | - G. Illerhaus
- Department of Haematology/Oncology and Palliative Care; Klinikum Stuttgart; Stuttgart Germany
| | - A. Herrera
- Department of Hematology/Hematopoietic Cell Transplantation; City of Hope, Duarte USA
| | - A. Masood
- Global Clinical Research; Bristol-Myers Squibb; Lawrenceville USA
| | - M. Shipp
- Center for Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| |
Collapse
|
|
10
|
Batlevi C, Alperovich A, Ni A, Soumerai J, Smith K, Ying Z, Caron P, Drullinsky P, Gerecitano J, Hamilton A, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz C, Noy A, Palomba M, Portlock C, Sauter C, Straus D, Zelenetz A, Seshan V, Younes A. DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_92] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | - A. Ni
- Biostatistics, MKSCC; New York USA
| | | | | | - Z. Ying
- Hematology; Peking University Cancer Hospital; Beijing China
| | | | | | | | | | | | | | | | | | | | | | - A. Noy
- Lymphoma, MSKCC; New York USA
| | | | | | | | | | | | | | | |
Collapse
|
|
11
|
Batlevi C, Hamlin P, Matasar M, Gerecitano J, Drullinsky P, Hamilton A, Straus D, Horwitz S, Kumar A, Moskowitz C, Moskowitz A, Zelenetz A, Ahsanuddin S, Callan D, Freidin B, Porzio R, Soiffer J, Copeland A, Dang T, Rademaker J, Schoder H, Ni A, Younes A. PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_38] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Batlevi
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Hamlin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Matasar
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Gerecitano
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Drullinsky
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Hamilton
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - D. Straus
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Horwitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Kumar
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Moskowitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Moskowitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Zelenetz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Ahsanuddin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - D. Callan
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - B. Freidin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Porzio
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Soiffer
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Copeland
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - T. Dang
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Rademaker
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - H. Schoder
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Younes
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
|
12
|
Soumerai J, Ni A, Batlevi C, Alperovich A, Bantilan K, Palomba M, Gerecitano J, Noy A, Hamlin P, Moskowitz C, Copeland A, Matasar M, Drullinsky P, Hamilton A, Horwitz S, Intlekofer A, Kumar A, Moskowitz A, Portlock C, Sauter C, Straus D, Caron P, Ying Z, Smith K, Younes A, Zelenetz A. TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J.D. Soumerai
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Batlevi
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Alperovich
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - K.S. Bantilan
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Palomba
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - J.F. Gerecitano
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Noy
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Hamlin
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C.H. Moskowitz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A.R. Copeland
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - M.J. Matasar
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - P.R. Drullinsky
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Hamilton
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - S.M. Horwitz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A.M. Intlekofer
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Kumar
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Moskowitz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Portlock
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Sauter
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - D.J. Straus
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Caron
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - Z. Ying
- Medicine, Royal Marsden Hospital; Beigene China
| | - K. Smith
- Medicine, Royal Marsden Hospital; London UK
| | - A. Younes
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| | - A.D. Zelenetz
- Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
|
13
|
Kumar A, Casulo C, Advani R, Budde E, Barr P, Batlevi C, Chen R, Constine L, Courtien A, Dandapani S, Drullinsky P, Friedberg J, Hamlin P, Hoppe R, Matasar M, McArthur G, Miller S, Moskowitz A, Noy A, Schoder H, Straus D, Yang J, Younes A, Zelenetz A, Yahalom J, Moskowitz C. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED-SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Kumar
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - C. Casulo
- Hematology/Oncology, Wilmot Cancer Institute; University of Rochester; Rochester NY USA
| | - R. Advani
- Hematology/Oncology, Stanford Cancer Institute; Stanford University; Stanford CA USA
| | - E. Budde
- Hematology/Oncology; City of Hope National Medical Center; Duarte CA USA
| | - P.M. Barr
- Hematology/Oncology, Wilmot Cancer Institute; University of Rochester; Rochester NY USA
| | - C.L. Batlevi
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - R. Chen
- Hematology/Oncology; City of Hope National Medical Center; Duarte CA USA
| | - L.S. Constine
- Hematology/Oncology, Wilmot Cancer Institute; University of Rochester; Rochester NY USA
| | - A.I. Courtien
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - S.V. Dandapani
- Hematology/Oncology; City of Hope National Medical Center; Duarte CA USA
| | - P. Drullinsky
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - J.W. Friedberg
- Hematology/Oncology, Wilmot Cancer Institute; University of Rochester; Rochester NY USA
| | - P.A. Hamlin
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - R.T. Hoppe
- Hematology/Oncology, Stanford Cancer Institute; Stanford University; Stanford CA USA
| | - M.J. Matasar
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - G.N. McArthur
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - S.T. Miller
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - A.J. Moskowitz
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - A. Noy
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - H. Schoder
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - D.J. Straus
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - J. Yang
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - A. Younes
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - A.D. Zelenetz
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - J. Yahalom
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - C.H. Moskowitz
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| |
Collapse
|